Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Recent & Breaking News (TSXV:ARCH)

Arch Biopartners Announces Start of Phase I Human Trial for Metablok

GlobeNewswire June 19, 2019

Arch Biopartners Closes Convertible Note Financing

GlobeNewswire May 22, 2019

Arch Biopartners Arranges Convertible Note Financing

GlobeNewswire May 17, 2019

Arch Biopartners Receives Approval to Perform Phase I Clincial Trial for Metablok in Australia

GlobeNewswire March 19, 2019

Arch Biopartners Awarded NRC-IRAP Funding to Further Develop Metablok Drug Program

GlobeNewswire February 7, 2019

Arch Biopartners Closes Convertible Note Financing

GlobeNewswire January 29, 2019

Arch Biopartners Arranges Convertible Note Financing

GlobeNewswire January 24, 2019

Arch Biopartners Forms New Subsidiary to Pursue a Phase I Trial in Australia for Metablok (LSALT Peptide)

GlobeNewswire December 11, 2018

Arch Biopartners Provides Toxicology Update for Metablok

GlobeNewswire October 29, 2018

Arch Biopartners Announces Completion of GMP Manufacturing of Metablok Vials

Canada NewsWire September 26, 2018

Arch Biopartners Engages Dalton Pharma Services for GMP Manufacturing of Metablok

Canada NewsWire August 14, 2018

Arch Biopartners Receives $332,750 From the Exercise of Warrants

GlobeNewswire June 26, 2018

Arch Biopartners to Seek Regulatory Guidance From the U.S FDA for AB569

GlobeNewswire June 19, 2018

Arch Biopartners Announces Listing on OTCQB Exchange

GlobeNewswire May 16, 2018

Arch Biopartners Completes Pre-IND Meeting with U.S. FDA on LSALT Peptide for Preventing Acute Kidney Injury in Cardiac Surgery Patients

GlobeNewswire May 8, 2018

Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic Resistance

GlobeNewswire March 27, 2018

Arch Biopartners Granted Pre-Ind Meeting With FDA for Candidate Drug to Prevent Acute Kidney Injury

GlobeNewswire March 21, 2018

Arch Biopartners Closes $1.25M Non-Brokered Private Placement Financing

GlobeNewswire March 9, 2018

Arch Biopartners Announces Start of GMP Manufacturing for Metablok at CSBio

GlobeNewswire February 27, 2018

Arch Biopartners Closes Convertible Note Financing

GlobeNewswire February 16, 2018